January 30, 2016
MedImpact — There are several challenges associated with managing specialty drugs, from both a cost and utilization perspective. A significant portion of the drug pipeline is composed of drugs for orphan diseases for which there are no other effective treatments. There also are a large number of approvals for cancer treatments with dire prognoses.
The newer therapies are given in combination with other specialty oncolytics which can double the cost of treatment.